ABBOTT has secured an exclusive
license for several novel biomarkers
from Stanford University.
According to Abbott the novel
biomarkers will be used to aid in
the development of a molecular
diagnostic test which would
differentiate aggressive from
nonaggressive prostate cancer.
“Developing a clinically validated
prostate cancer prognostic assay
with actionable data represents the
'holy grail' in improving disease
management,” said Stanford
University Medical Centre’s James
Brooks, Associate Professor,
Department of Urology.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 18 Apr 12
Pharmacy Daily is Australia's favourite online publication dedicated to the pharmacy industry. The publication launched in March 2007 and is distributed every day by email to pharmacists across the country. MORE